Germany Oncology Market Analysis: Cancer Diagnostics, Cancer Treatment Drugs, Cancer Therapy (Targeted Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy, Others), Applications (Blood Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Bladder Cancer, Head & Neck Cancer, Prostate Cancer, and Others), States: North Rhine-Westphalia, Bayern, Baden-Württemberg, Lower Saxony, Hesse and others

Germany Oncology market size is estimated to be $XX million in 2022. It is not surprising that cancer patients have a high mortality rate. In Germany, where many patients had cancer for many years, the rate is substantially different. In Germany, a large percentage of cancer patients survive into old age and pass away for reasons unrelated to oncology. In Germany, several oncologic conditions can be healed. The patient is often considered to be cured if there is no sign of the condition within five years of treatment. Early on, before the tumor has spread and when there are no metastases, malignant oncologic disorders are considerably easier to treat. An estimated 233,000 women in 2018 and there were 265,000 new cancer diagnoses in men in Germany. As a result, the total annual number of new cases has remained constant for the past ten years at roughly 500,000. Because of the aging population, cancer incidence rates have generally decreased, albeit there are some inconsistent trends for the various forms of cancer.

In Germany, cancer claimed the lives of almost 231,000 people in 2019—125,000 males and 106,000 women. The Federal Statistical Office (Destatis) states that a quarter of all fatalities were brought on by cancer in time for World Cancer Day

Lung cancer is the number one cancer-related mortality. In Germany, it is responsible for 14% of cancer deaths in women and 25% of cancer fatalities in men. Lung cancer is a significant contributor to the overall Germany oncology market.

In both developing and industrialized nations, breast cancer is the most prevalent malignancy among women. In Germany, 68,950 women received a breast cancer diagnosis in 2016, while 18,570 women passed away from the illness.

Although liver cancer is rather uncommon, it is one of the leading causes of cancer death and, as a result, has one of the worst prognoses. In Germany, there are roughly 8,000 fatalities per year and 9,000 new cases that are diagnosed. Malignant liver tumors will form in one in 88 men and one in 190 women in Germany during their lifetimes.

According to the recent WHO data. In 2020 Germany has attained 6,193 or 0.88% of mortalities from Bladder Cancer.

Overall prostate cancer incidence increased in Germany over the observation period from 56.0 per 100,000 in 1999 to 76.0 per 100,000 in 2010, with patients aged 65–74 experiencing the highest increases

Reason for increment in Germany

There several reasons for the rising cancer in the country such as usage of tobacco, obesity, alcohol, unhealthy lifestyles and others. Some viral infections, like those caused by the human papillomavirus (HPV), certain chemicals, and exposure to radiation and also the other factors responsible for cancer.

Germany Oncology Market by States

• North Rhine-Westphalia oncology market
• Bayern oncology market
• Baden-Württemberg oncology market
• Lower Saxony oncology market
• Hesse oncology market
• Rest of Germany

Germany oncology market is further divided into States. 5 of its states namely North Rhine-Westphalia, Bayern, Baden-Württemberg, Lower Saxony and Hesse account for a major portion of Germany oncology market.

Germany Oncology Market Segments

Datavagyanik has covered each oncology in detail in terms of market size, sales volume, growth forecast. The segment and sub segment level categorization covered in the report are:

• Cancer Diagnostics
  • Biopsy
  • Imaging
  • Immunohistochemistry
  • Tumor Biomarkers Test
  • In Situ Hybridization
  • Liquid Biopsy
• Cancer Treatment Drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and Others)
• Cancer Treatment Therapy
  • Targeted Therapy
  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Others
• Applications
  • Blood Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Liver Cancer
  • Bladder Cancer
  • Head & Neck Cancer
  • Prostate Cancer
  • Others

Key questions answered in the Germany Oncology Market Analysis Report:

• What is the overall oncology market size in Germany and how is the demand rising and what is market for each cancer type (Blood Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Bladder Cancer, Head & Neck Cancer, Prostate Cancer, Others)?
• What is the market size for cancer diagnostics (Biopsy, Imaging, Immunohistochemistry, Tumor, Biomarkers Test, In Situ Hybridization, Liquid Biopsy) in Germany?
• What is the market size for cancer treatment drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and Others) in Germany?
• What is the market size for cancer treatment by therapy (Targeted Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy, Others) in Germany?
• Who are the top market players by market share, in each product segment?
• Which is the fastest growing business/ product segment?
• What should be the business strategies and Go to Market strategies?

Oncology in Germany: Report Deliverables

1. Summary Statistics
   • Oncology in Germany Market Attractiveness Analysis

• Oncology Diagnostics Market
• Oncology Drugs
• Therapies/Treatment Type

1. Oncology in Germany Market Analysis, by Segment (state level analysis)
   • Overview
   • Historical Market size ($Million), (2017 – 2021)
   • Market size ($Million), and Forecasts (2022 – 2027)
2. Market Analysis by Segment (state level analysis)
   • End Users (Hospitals, Diagnostics Centers, others)
   • Application (Blood Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Bladder Cancer, Head & Neck Cancer, Prostate Cancer, Others)
3. Region wise analysis

• North Rhine-Westphalia revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
• Bayern revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
• Lower Saxony revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
• Hesse revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
• Rest of Germany revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)

5. Pricing analysis
   • Cancer diagnostics and treatment cost in Germany
   • Cancer drug cost in Germany
6. Market forecast for 10 years
7. Investment strategies